@prefix nt: .
@prefix orcid: .
@prefix bl: .
@prefix nkg: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo;
a np:Nanopublication .
}
sub:assertion {
a bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP.";
bl:has_population_context sub:context;
bl:provided_by ;
bl:publications ;
bl:relation nkg:OffLabelIndication .
sub:context a bl:Cohort;
rdfs:label "Adults";
bl:has_phenotype .
a bl:Drug .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-08-24T20:13:50.640391"^^xsd:dateTime .
}
sub:pubInfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "F6PcR5J56A0r2WUq5Bt+W3zwKdEyn99Proh4djvGxPE1opq7kotapHBV3cKM8icV1RdZoeVBi6V8WateJ2bvZf5W7m4sx9Mz6VcVjS8PPf/sAKZlieYgN3joEdyhGvBdI6wfXA3MhrMmgMexKXYi3EDmzbORXRfgQPQHall1mDs=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2021-08-24T20:13:50.640391"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-7641-6446;
nt:wasCreatedFromTemplate .
}